Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
- Sponsor
- The First Affiliated Hospital of Soochow University
- Study ID
- NCT05855122
- Phase
- PHASE4
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tocilizumab — DRUGPateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
Study Details
Background: Autologous hematopoietic stem cell transplantation(ASCT) is an important part treatment for patients with multiple myeloma. Retrospective analysis from our center showed that incidence of oral mucositis and gastrointestinal symptoms was higher during ASCT for melphalan as conditioning regimen in patients with multiple myeloma. Objective: Safety and optimization of ASCT-related symptom burden of tocilizumab for melphalan as a conditioning regimen in ASCT for multiple myeloma is explored. Methods: The patient who is enrolled will be randomly divided into two groups in a proportion of 1:1 to respectively receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells or not. There will be enroll 48 patients according to inclusion and exclusion criteria totally. Adverse events and MDASI score during ASCT between two groups will be recorded and analyzed. Primary endpoint: MDASI, Security; Secondary endpoints: time to neutrophil engraftment; time of platelet implantation; efficacy (ORR) after autologous hematopoietic stem cell transplantation.
Key Dates
- Start date
- Apr 17, 2023
- Status verified
- Jun 2023
- Primary completion
- Aug 31, 2024
- Completion
- Dec 31, 2024
Study Design
- Enrollment
- 48 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Tocilizumab
- No Intervention: no-Tocilizumab
Primary Outcome Measure
MDASI questionnaire [ Time Frame: day -7~day 100 after stem cells transfusion ]
Central Contacts
- chengcheng Fu, PhD051267781856
Related Studies
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Family Study of Lymphoproliferative DisordersRecruiting · Mayo Clinic · Rochester, Minnesota
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruiting · Boston Medical Center · Boston, Massachusetts
- Collection of Tissue Samples for Cancer ResearchRecruiting · National Cancer Institute (NCI) · Sacramento, California